Pulmonx Q1 revenue $14.5M (+35% YoY); reaffirms FY 2023 guidance

Pulmonx Corp

2023-Q1 EPS reported -$0.42 revenue$14,535,000

Worldwide revenue $14.5M, up 35% YoY; U.S. revenue $9.3M (+55% YoY).
Gross margin 73% vs. 75% in Q1 2022; net loss $15.9M ($0.42 per share).
Adjusted EBITDA loss $11.2M vs. $11.8M in prior-year period.
Added 15 new U.S. Zephyr Valve treatment centers in Q1 2023.
Full-year 2023 guidance reaffirmed: revenue $63-65M; gross margin 73-74%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pulmonx Corp reported first quarter of 2023 ended March 31, 2023 results: revenue $14.5 million, EPS $0.42 per share. Guidance reaffirmed.

Period: first quarter of 2023 ended March 31, 2023
Revenue: $14.5 million
EPS: $0.42 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

invasive treatments for lung disease, today reported financial results for the first quarter of 2023 ended March 31, 2023. Recent Highlights • Recorded worldwide revenue of $14.5 million in the first quarter of 2023, a 35% increase over the same period last year and an increase of 37% on a constant currency basis • Delivered $9.3 million in U.S. revenue in the

View on SEC.gov

Browse all earnings releases →

Pulmonx Corp filing history →

Source: SEC EDGAR

accession 0001127537-23-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.